• Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.

      Korpanty, Grzegorz; Smyth, Elizabeth; Sullivan, Laura A; Brekken, Rolf A; Carney, Desmond N; Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland. greg.korpanty@gmail.com (2010-01)
      Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.
    • Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer.

      Baird, Anne-Marie; Gray, Steven G; O'Byrne, Kenneth J; Thoracic Oncology Research Group, Institute of Molecular Medicine, Trinity College, Dublin, Ireland. (2011-01)
      Angiogenesis may play a role in the pathogenesis of Non-Small Cell Lung cancer (NSCLC). The CXC (ELR(+)) chemokine family are powerful promoters of the angiogenic response.